FY2025 Earnings Estimate for Cytokinetics Issued By B. Riley

Cytokinetics, Incorporated (NASDAQ:CYTK) – Equities research analysts at B. Riley dropped their FY2025 earnings per share estimates for Cytokinetics in a research report issued on Monday, September 22nd. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will earn ($5.72) per share for the year, down from their prior forecast of ($5.62). B. Riley currently has a “Buy” rating and a $80.00 target price on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. B. Riley also issued estimates for Cytokinetics’ Q4 2025 earnings at ($1.64) EPS, FY2026 earnings at ($6.04) EPS, FY2027 earnings at ($5.46) EPS, FY2028 earnings at ($3.39) EPS and FY2029 earnings at $0.21 EPS.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.12) EPS for the quarter, beating analysts’ consensus estimates of ($1.34) by $0.22. The firm had revenue of $66.77 million for the quarter, compared to analysts’ expectations of $1.95 million. The firm’s revenue was up 26727.3% compared to the same quarter last year. During the same quarter last year, the company posted ($1.31) EPS.

Other analysts have also recently issued research reports about the company. JMP Securities reiterated a “market outperform” rating and set a $78.00 price objective on shares of Cytokinetics in a research report on Tuesday, September 2nd. Barclays lifted their price target on shares of Cytokinetics from $53.00 to $71.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 3rd. JPMorgan Chase & Co. dropped their price target on shares of Cytokinetics from $71.00 to $53.00 and set an “overweight” rating on the stock in a research note on Monday, June 9th. Raymond James Financial initiated coverage on Cytokinetics in a research report on Wednesday, July 30th. They issued a “market perform” rating for the company. Finally, Wall Street Zen upgraded Cytokinetics from a “strong sell” rating to a “hold” rating in a research report on Sunday, August 10th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Cytokinetics has a consensus rating of “Moderate Buy” and a consensus target price of $75.71.

Cytokinetics Stock Performance

Cytokinetics stock opened at $48.29 on Wednesday. The stock has a market cap of $5.78 billion, a PE ratio of -9.47 and a beta of 0.62. Cytokinetics has a one year low of $29.31 and a one year high of $59.39. The stock has a fifty day moving average of $41.38 and a 200 day moving average of $38.14.

Insiders Place Their Bets

In related news, CEO Robert I. Blum sold 5,000 shares of the stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $49.77, for a total transaction of $248,850.00. Following the completion of the sale, the chief executive officer owned 373,108 shares in the company, valued at approximately $18,569,585.16. This trade represents a 1.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Edward M. Md Kaye sold 6,756 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $50.00, for a total value of $337,800.00. Following the sale, the director owned 23,230 shares of the company’s stock, valued at $1,161,500. This represents a 22.53% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,756 shares of company stock worth $1,452,550 over the last quarter. 2.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Cytokinetics

Institutional investors have recently made changes to their positions in the business. EverSource Wealth Advisors LLC grew its position in shares of Cytokinetics by 723.7% during the second quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 673 shares in the last quarter. Fifth Third Bancorp grew its position in shares of Cytokinetics by 42.2% during the first quarter. Fifth Third Bancorp now owns 981 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 291 shares in the last quarter. Hantz Financial Services Inc. grew its position in shares of Cytokinetics by 2,872.7% during the second quarter. Hantz Financial Services Inc. now owns 1,308 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 1,264 shares in the last quarter. Parallel Advisors LLC grew its position in shares of Cytokinetics by 500.5% during the first quarter. Parallel Advisors LLC now owns 1,099 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 916 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in shares of Cytokinetics by 281.0% during the first quarter. GAMMA Investing LLC now owns 1,120 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 826 shares in the last quarter.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.